全文获取类型
收费全文 | 24497篇 |
免费 | 1909篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 173篇 |
儿科学 | 595篇 |
妇产科学 | 417篇 |
基础医学 | 3870篇 |
口腔科学 | 411篇 |
临床医学 | 2593篇 |
内科学 | 4933篇 |
皮肤病学 | 343篇 |
神经病学 | 2092篇 |
特种医学 | 921篇 |
外科学 | 3394篇 |
综合类 | 224篇 |
一般理论 | 34篇 |
预防医学 | 2364篇 |
眼科学 | 367篇 |
药学 | 2002篇 |
中国医学 | 31篇 |
肿瘤学 | 1707篇 |
出版年
2023年 | 190篇 |
2022年 | 233篇 |
2021年 | 637篇 |
2020年 | 431篇 |
2019年 | 595篇 |
2018年 | 694篇 |
2017年 | 570篇 |
2016年 | 586篇 |
2015年 | 680篇 |
2014年 | 851篇 |
2013年 | 1172篇 |
2012年 | 1710篇 |
2011年 | 1628篇 |
2010年 | 980篇 |
2009年 | 869篇 |
2008年 | 1438篇 |
2007年 | 1397篇 |
2006年 | 1321篇 |
2005年 | 1272篇 |
2004年 | 1191篇 |
2003年 | 1067篇 |
2002年 | 917篇 |
2001年 | 430篇 |
2000年 | 387篇 |
1999年 | 380篇 |
1998年 | 247篇 |
1997年 | 185篇 |
1996年 | 193篇 |
1995年 | 139篇 |
1994年 | 164篇 |
1993年 | 135篇 |
1992年 | 275篇 |
1991年 | 258篇 |
1990年 | 295篇 |
1989年 | 297篇 |
1988年 | 269篇 |
1987年 | 227篇 |
1986年 | 242篇 |
1985年 | 248篇 |
1984年 | 194篇 |
1983年 | 170篇 |
1982年 | 104篇 |
1981年 | 92篇 |
1979年 | 123篇 |
1978年 | 89篇 |
1977年 | 67篇 |
1975年 | 74篇 |
1974年 | 104篇 |
1973年 | 98篇 |
1972年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Anders Elm Pedersen Esben Gjerløff Wedebye Schmidt Jesper Freddie Sørensen Carsten Faber Boye Schnack Nielsen Kim Holmstrøm Silje Haukali Omland Peter Tougaard Søren Skov Bo Bang 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(7):547-555
TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large‐scale studies are warranted to investigate TL1A as a biomarker. 相似文献
5.
6.
Thomas Asendorf Robin Henderson Heinz Schmidli Tim Friede 《Statistics in medicine》2019,38(9):1503-1528
In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis. 相似文献
7.
8.
Marie Warrer Petersen Tine Sylvest Meyhoff Marie Helleberg Maj-Brit Nørregaard Kjær Anders Granholm Carl Johan Steensen Hjortsø Thomas Steen Jensen Morten Hylander Møller Peter Buhl Hjortrup Mik Wetterslev Gitte Kingo Vesterlund Lene Russell Vibeke Lind Jørgensen Klaus Tjelle Thomas Benfield Charlotte Suppli Ulrik Anne Sofie Andreasen Thomas Mohr Morten H. Bestle Lone Musaeus Poulsen Mette Friberg Hitz Thomas Hildebrandt Lene Surland Knudsen Anders Møller Christoffer Grant Sølling Anne Craveiro Brøchner Bodil Steen Rasmussen Henrik Nielsen Steffen Christensen Thomas Strøm Maria Cronhjort Rebecka Rubenson Wahlin Stephan Jakob Luca Cioccari Balasubramanian Venkatesh Naomi Hammond Vivekanand Jha Sheila Nainan Myatra Christian Gluud Theis Lange Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375
Introduction
Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.Methods
The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.Discussion
The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.9.
10.
Kate Ridley Tim S Olds Alison Hill 《The international journal of behavioral nutrition and physical activity》2006,3(1):10-11